Next month's launch of a Medicare program providing weight-loss drugs for $50 a month is expected to unleash pent-up demand for Wegovy, Zepbound and other blockbuster treatments — and create new bottlenecks at doctors' offices. Clinicians worry that could also give short shrift to patient counseling on how to take the injectables and pills, adjust dosages and deal with side effects.
The program stems from a deal President Trump struck with Eli Lilly and Novo Nordisk to cut prices for their diabetes and anti-obesity drugs in exchange for access to more patients. Medicare has been prohibited by law from covering weight-loss drugs until now.
Roughly 14 million Medicare beneficiaries are overweight or obese, according to KFF. Providers are bracing for an onslaught beginning July 1. "I have a long list of people who are just holding their breath until July 1, who just could not afford the medication before," Christopher Weber, a board member of the Obesity Medicine Association, told Axios.
The surge could test an already burdened system as seniors seek new GLP-1 prescriptions. It may become one of the biggest drug rollouts ever, according to Axios. Yet patient education and follow-up care risk being squeezed as clinics scramble to meet demand.
Some experts caution that without adequate infrastructure, adverse events or improper use could undermine the program's benefits. The burden on primary care, already strained, may worsen before solutions emerge.